Abstract:Immune thrombocytopenia (ITP) comprises a syndrome of diverse disorders that have in common immune-mediated thrombocytopenia, but that differ with respect to pathogenesis, natural history and response to therapy. ITP may occur in the absence of an evident predisposing etiology (primary ITP) or as a sequela of a growing list of associated conditions (secondary ITP). Primary ITP remains a diagnosis of exclusion and must be differentiated from non-autoimmune etiologies of thrombocytopenia and secondary causes of ITP. The traditional objective of management is to provide a hemostatic platelet count (> 20-30 × 10(9) L(-1) in most cases) while minimizing treatment-related toxicity, although treatment goals should be tailored to the individual patient and clinical setting. Corticosteroids, supplemented with either intravenous immune globulin G or anti-Rh(D) as needed, are used as upfront therapy to stop bleeding and raise the platelet count acutely in patients with newly diagnosed or newly relapsed disease. Although most adults with primary ITP respond to first-line therapy, the majority relapse after treatment is tapered and require a second-line approach to maintain a hemostatic platelet count. Standard second-line options include splenectomy, rituximab and the thrombopoietin receptor agonists, romiplostim and eltrombopag. Studies that directly compare the efficacy, safety and cost-effectiveness of these approaches are lacking. In the absence of such data, we do not favor a single second-line approach for all patients. Rather, we consider the pros and cons of each option with our patients and engage them in the decision-making process.

Protocol for the study and treatment of primary immune thrombocytopenia: ITP-2018

Novel Therapies to Address Unmet Needs in ITP

Real-life clinical practice in Spain in the setting of new drug availability for ITP treatment. A Delphi-based Spanish expert panel consensus

Management of children and adolescents with primary immune thrombocytopenia: controversies and solutions

Primary immune thrombocytopenia in adults: Belgian recommendations for diagnosis and treatment anno 2021 made by the Belgian Hematology Society

Advances in the pathophysiology of primary immune thrombocytopenia

ITP in the 21st Century

Immune Thrombocytopenia Nomenclature, Consensus Reports, and Guidelines: What Are the Consequences for Daily Practice and Clinical Research?

Chinese guidelines for treatment of adult primary immune thrombocytopenia

[Management of pediatric immune thrombocytopenia]

Current Management of Primary Immune Thrombocytopenia

Contemporary management of primary immune thrombocytopenia in adults

Management and Treatment of Primary Immune Thrombocytopenia in Children

Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives

2022 Review of the 2019 American Society of Hematology Guidelines on Immune Thrombocytopenia

What's in a name: defining pediatric refractory ITP

Investigational drugs for immune thrombocytopenia

A Review of Pathogenesis and Treatment Options

Current treatment options for primary immune thrombocytopenia

Reference guide for the diagnosis of adult primary immune thrombocytopenia, 2023 edition

Treatments for Primary Immune Thrombocytopenia: A Review